6 To 7 Amino Acid Residues In Defined Sequence Patents (Class 530/329)
  • Patent number: 10287320
    Abstract: The present invention provides a peptide which: (i) consists of 10 to 16 amino acids; (ii) has at least 8 cationic amino acids with either (a) a side chain comprising a guanidinium group, or (b) a side chain comprising an amino group, of which no more than 7 are consecutive; and (iii) has 2 or 3 tryptophan residues which are not both, or not all, consecutive, said peptide optionally in the form of a salt, ester or amide, or a peptidomimetic of said peptide. The invention further relates to pharmaceutical compositions containing these compounds, the use of these compounds in therapy, particularly as anti-tumor (e.g. anti-lymphoma) agents and non-therapeutic uses of these compounds.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: May 14, 2019
    Assignee: Universitetet i Tromsø—Norges Arktiske Universit
    Inventors: John Sigurd Svendsen, Øystein Rekdal, Johannes Eksteen
  • Patent number: 10246485
    Abstract: The present invention relates to a method for concentrating von Willebrand Factor (VWF) from an aqueous solution comprising precipitating the VWF by providing calcium ions and phosphate ions and the subsequent resolubilization of the VWF by means of an aqueous solution comprising a calcium complexing compound.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: April 2, 2019
    Assignee: CSL LIMITED
    Inventors: Holger Lind, Sonja Beckmann-Scheld, Katharina Propp
  • Patent number: 10117887
    Abstract: Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of “warhead” anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compositions comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, undesirable fibrosis, and undesirable inflammation.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: November 6, 2018
    Assignee: BACH BIOSCIENCES, LLC
    Inventors: William W. Bachovchin, Hung-sen Lai, David G. Sanford, Sarah E. Poplawski, Wengen Wu
  • Patent number: 10065988
    Abstract: Compounds of Formulas I: and shorter variants thereof are described, along with solid supports having such compounds coupled thereto, and the use thereof as affinity ligands for antibodies.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: September 4, 2018
    Assignee: Stefano Menegatti
    Inventor: Stefano Menegatti
  • Patent number: 10004828
    Abstract: Novel peptide-based hydrogels, composed of short aromatic peptides (e.g., homodipeptides of aromatic amino acid residues) are disclosed. The hydrogels are characterized by remarkable rigidity and biocompatibility. Further disclosed are uses of these hydrogels in applications such as tissue engineering, drug delivery, cosmetics, implantation, packaging and the like. Further disclosed are processes and kits for preparing these hydrogels.
    Type: Grant
    Filed: October 15, 2006
    Date of Patent: June 26, 2018
    Assignee: Romat at Tel-Aviv University Ltd.
    Inventors: Ehud Gazit, Assaf Mahler, Meital Reches
  • Patent number: 9850285
    Abstract: The present invention provides processes for preparation of eptifibatide that involve coupling of amino acids in a (2+5), (4+3) and (3+4) sequence method. The invention further provides products produced by the described processes, novel compounds that can be used as synthetic intermediates for the preparation of eptifibatide.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: December 26, 2017
    Assignee: LAURUS LABS LIMITED
    Inventors: Subha Nair Velayudhan, Ravindra Babu Bollu, Venkata S. Indukuri, Seeta R. Gorantla, Venkata S. Kallam, Bala M. Madivada
  • Patent number: 9789155
    Abstract: This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: October 17, 2017
    Assignee: Emory University
    Inventors: Larry James Young, Meera E. Modi
  • Patent number: 9737571
    Abstract: A composition comprising an extract from an aquatic organism is disclosed. The composition is capable of preventing adhesion of a cell to a surface and is devoid of cytotoxic or cytostatic activity. Medical devices comprising same and methods for preventing or treating a pathological infection using same are also disclosed.
    Type: Grant
    Filed: September 21, 2008
    Date of Patent: August 22, 2017
    Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Amir Zlotkin, Eliahu Zlotkin, Amir Zlotkin
  • Patent number: 9597410
    Abstract: Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: March 21, 2017
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai, Sarah E. Poplawski
  • Patent number: 9579283
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: February 28, 2017
    Assignees: STC.UNM, Sandia Corporation
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Cheryl L. Willman
  • Patent number: 9504758
    Abstract: An antibody comprising a GlcNAc—S(A)x substituent is disclosed, wherein S(A)x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc—S(A)x substituent is bonded to the antibody via C1 of the N-acetylglucosamine of said GlcNAc—S(A)x substituent, and wherein said N-acetylglucosamine is optionally fucosylated. Also disclosed is an antibody-conjugate, in particular to an antibody-conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1). Also disclosed is a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 29, 2016
    Assignee: SynAffix B.V.
    Inventors: Floris Louis Van Delft, Remon Van Geel, Maria Antonia Wijdeven
  • Patent number: 9365618
    Abstract: This invention provides a TNFR2 expression-inducing composition including as an active ingredient a peptide having TNFR2 expression-inducing activity, and a method for producing cells that express TNFR2 selectively by use of the composition. The cell production method provided by this invention includes: culturing at least one species of cells capable of expressing TNF receptor 2, and supplying the cells with a synthetic peptide consisting of a nuclear localization signal sequence (NLS) or a nucleolar localization signal sequence (NoLS) to enhance TNFR2 expression in the cells.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: June 14, 2016
    Assignee: TOAGOSEI CO. LTD.
    Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida, Mikio Niwa
  • Patent number: 9320698
    Abstract: Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory pep tides in a topical formulation. Preferred octapeptide sequences are internally rich in tryptophan and/or tyrosine or arginine. The present invention is further directed to kits and compositions containing the present peptides, and methods of treatment of conditions involving expression of tyrosinase, in which the present peptides are administered topically for the treatment of conditions involving melanocyte activity in the skin.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: April 26, 2016
    Assignee: Escape Therapeutics, Inc.
    Inventors: Basil M. Hantash, Anan Abu Ubeid
  • Patent number: 9303065
    Abstract: The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: April 5, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael G. Kornacker, Claudio Mapelli, Douglas James Riexinger
  • Patent number: 9242015
    Abstract: The invention provides compounds and a method for imaging aggregated ?-synuclein, e.g., Lewy bodies or Lewy neurites, in a tissue or organ.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: January 26, 2016
    Assignee: The General Hospital Corporation
    Inventor: Brian Bacskai
  • Patent number: 9156885
    Abstract: The present invention provides processes for preparation of eptifibatide that involve coupling of amino acids in a (2+5), (4+3) and (3+4) sequence method. The invention further provides products produced by the described processes, novel compounds that can be used as synthetic intermediates for the preparation of eptifibatide.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: October 13, 2015
    Assignee: Laurus Labs Private Ltd.
    Inventors: Subha Nair Velayudhan, Ravindra Babu Bollu, Venkata Sunil Kumar Indukuri, Seeta Ramanjaneyulu Gorantla, Venkata Siva RamaKrishna Reddy Kallam, Bala Muralikrishna Madivada
  • Patent number: 9115058
    Abstract: The invention relates to a process for preparing optically active ?-aminoacetals by resolution of a racemic mixture or of a mixture of enantiomers via the formation of diastereoisomeric salts, and also novel intermediates in the form of diastereoisomeric salts.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: August 25, 2015
    Assignee: WEYLCHEM LAMOTTE S.A.S.
    Inventors: Muriel Albalat, Geraldine Primazot, Didier Wilhelm, Jean-Claude Vallejos
  • Patent number: 9115177
    Abstract: The method of the preparation of micafungin sodium comprises the step of mixing the weak base and the aqueous solution containing micafungin acid (the structure is illustrated by formula I) or the mixed aqueous solution containing the compound of formula I and organic solvent in order to obtain the sodium salt of micafungin (the structure is illustrated by formula II).
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: August 25, 2015
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Guangjun Jiao, Shidong Liu, Bingming He, Zhijun Tang, Xiaoming Ji
  • Patent number: 9078861
    Abstract: Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: July 14, 2015
    Assignee: Acorda Therapeutics Inc.
    Inventors: Anthony O. Caggiano, Anthony J. Bella, Jennifer F. Iaci
  • Publication number: 20150148523
    Abstract: The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a proline derivative to provide cyclically constrained ?-substituted-?-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to cyclically constrained protected ?-amino acid residues, which are essential for systematic conformational studies of ?-peptide foldamers. New methods are also provided to prepare other ?-amino acids and peptides. These new building blocks can be used to prepare foldamers, such as ?/?-peptide foldamers, that adopt specific helical conformations in solution and in the solid state.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 28, 2015
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Samuel Helmer Gellman, Li Guo, Michael Giuliano
  • Publication number: 20150148302
    Abstract: The present invention relates to compositions, including membrane permeable complexes, comprising a Caspase 2 activation inhibitory peptide having the amino acid sequence AFDAFC as well as methods of using the same for the treatment of neurodegenerative conditions associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease.
    Type: Application
    Filed: March 7, 2014
    Publication date: May 28, 2015
    Applicant: The Trustees of Columbia University in the city of New York
    Inventor: Carol M. Troy
  • Publication number: 20150148285
    Abstract: The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously.
    Type: Application
    Filed: May 8, 2014
    Publication date: May 28, 2015
    Applicant: National Tsing Hua University
    Inventors: Jya-Wei Cheng, Hui-Yuan Yu, His-Tsung Cheng
  • Publication number: 20150141347
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Patent number: 9035025
    Abstract: A method of producing a molecularly-imprinted material comprises synthesizing a peptide, oligosaccharide or oligonucleotide on a disposable surface modified support to produce a support surface-attached peptide, oligosaccharide or oligonucleotide, providing a selected monomer mixture, contacting the monomer mixture with the support surface-attached peptide, oligosaccharide or oligonucleotide, initiating polymerisation or at least one crosslinking reaction, dissolving or degrading the support surface-attached peptide, oligosaccharide or oligonucleotide and support, and obtaining molecularly imprinted material.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: May 19, 2015
    Assignee: MIP Technologies AB
    Inventors: Börje Sellergren, Maria Magdalena Titirici, Andrew J. Hall
  • Patent number: 9035021
    Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: May 19, 2015
    Assignee: Novartis AG
    Inventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
  • Publication number: 20150132328
    Abstract: The present invention relates to the field of human and veterinary medicine. The invention solves the problem associated with the lack of an agent for improving the immune response in immunosuppressed individuals, or with autoimmunity problems as well as infections; reducing the effects of the stress, combating tissue fibrosis; the need for anti-inflammatory agents; treatments for acute and chronic hepatitis, treatments against malignant processes and metastasis, as well as thrombocytopenia, both in humans and animals. The present invention comprises a molecular complex formed by a metallic ion and a peptide as novel compound, which is denominated as an immunomodulator metallopeptide hereafter abbreviated as IMMP. Claims also include the process for obtaining the complex, the use of the metallopeptide for producing a therapeutic or nutraceutic agent, and the use of that agent in humans and animals.
    Type: Application
    Filed: October 4, 2011
    Publication date: May 14, 2015
    Applicant: UNIVERSIDAD AUTONOMA DEL ESTADO DE MORELOS
    Inventors: Jorge Alberto Reyes Esparza, Maria de Lourdes Rodriguez Fragoso, Ana Laura Badillo Jimenez, Lorena Julieta Torres Aguilar, Lorenzo Ulises Martinez Osuna, Abril Arianna Martinez De Los Rios Corsino, Carlos Antonio Arjona Canul, Hugo Morales Rojas
  • Patent number: 9029327
    Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: May 12, 2015
    Assignee: Affiris AG
    Inventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
  • Patent number: 9029329
    Abstract: The invention relates to peptidic compounds of general formula (I) R1-(AA)n-X1-X2-Ile-Gln-Ala-Cys-Arg-Gly-X3-(AA)p-R2 as caspase-14 activators. The invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically acceptable medium, and to the use of said composition for preventing and/or repairing damage to deoxyribonucleic acid, for preventing and/or treating cutaneous signs of ageing and photo-ageing, and for improving the skin barrier function. The invention further relates to a cosmetic treatment method for preventing and/or treating cutaneous signs of ageing and photo-ageing, and for preventing and/or repairing damage caused by ultraviolet radiation.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: May 12, 2015
    Assignee: ISP Investments Inc.
    Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
  • Patent number: 9029502
    Abstract: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence
  • Publication number: 20150125392
    Abstract: AV?6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AV?6 mediated diseases.
    Type: Application
    Filed: December 11, 2014
    Publication date: May 7, 2015
    Inventors: Mark J. Howard, Danielle Dicara, John Marshall
  • Publication number: 20150126457
    Abstract: A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 7, 2015
    Inventors: Dennis J. Goebel, John Marshall
  • Publication number: 20150126456
    Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 7, 2015
    Inventors: Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
  • Publication number: 20150126450
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: May 7, 2015
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian
  • Publication number: 20150118698
    Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.
    Type: Application
    Filed: May 4, 2012
    Publication date: April 30, 2015
    Applicant: Nordic Biociences A/S
    Inventors: Natas[c]ha Barascuk Michaelsen, Federica Genovese, Morten Karsdal, Diana Julie Leeming
  • Publication number: 20150121569
    Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.
    Type: Application
    Filed: July 1, 2014
    Publication date: April 30, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNITERSITE PAUL SABATIER TOULOUSE III
    Inventors: Jean-Philippe COMBIER, Dominique LAURESSERGUES, Guillaume BECARD, Francois PAYRE, Serge PLAZA, Jerome CAVAILLE, Jerome CAVAILLE
  • Publication number: 20150119334
    Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.
    Type: Application
    Filed: June 3, 2013
    Publication date: April 30, 2015
    Applicant: Ben-Gurion niversity of the Negev Research and Development Authority
    Inventors: Hanna Rapaport, Anna Gittelman
  • Publication number: 20150119330
    Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: Patrick A. McGee, Kenneth W. Jackson, Victoria J. Christiansen
  • Publication number: 20150119340
    Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
  • Publication number: 20150119341
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Application
    Filed: December 30, 2014
    Publication date: April 30, 2015
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 9018352
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: April 28, 2015
    Assignee: Allegro Pharmaceuticals, Inc.
    Inventors: Michael J. Mackel, John Park
  • Publication number: 20150110797
    Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 23, 2015
    Inventors: Michal A. Rahat, Nitza Lahat, Miriam Walter, Haim Bitterman
  • Patent number: 9012603
    Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 21, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
  • Publication number: 20150104458
    Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.
    Type: Application
    Filed: August 26, 2014
    Publication date: April 16, 2015
    Applicant: Biomay AG
    Inventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
  • Publication number: 20150105327
    Abstract: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: Woojin An, Nouri Neamati, Kyunghwan Kim
  • Publication number: 20150104473
    Abstract: The invention is directed to a compound according to the formula [1] wherein R1 and R2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or 0 and R is —OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.
    Type: Application
    Filed: October 4, 2012
    Publication date: April 16, 2015
    Inventors: Ferdinand Antonius Ossendorp, Cornelis Johannes Maria Melief, Selina Khan, Dmitri Viktorovistj Filippov, Gijsbert Arie Van Der Marel
  • Publication number: 20150105335
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Richard Franklin
  • Publication number: 20150105316
    Abstract: This application describes compounds acting as, for example, ?-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Publication number: 20150104454
    Abstract: Embodiments of the invention are directed to a composition comprising a recombinant protein in soluble form wherein said recombinant protein comprises a portion of the Clostridium difficile toxin B sequence that comprises an epitope for anti-toxin B antibody. Other embodiments of the invention are directed to the generation of antibodies using peptide fragments of C. difficile toxin B.
    Type: Application
    Filed: September 13, 2012
    Publication date: April 16, 2015
    Applicant: Board of Regents of the University of Oklahoma
    Inventors: Jimmy D. Ballard, Jordi M. Melton, Latisha Heinlen, Elaine E. Hamm
  • Publication number: 20150104472
    Abstract: Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising X4WX5YX6 as defined herein and compositions comprising such are also provided. Methods of treating autoimmune disorders are provided.
    Type: Application
    Filed: July 15, 2014
    Publication date: April 16, 2015
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventor: Betty A. Diamond